Skip to main content
13 search results for:

Savolitinib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 22-07-2021 | Non-small-cell lung cancer | News | Article

    Savolitinib responses encouraging in MET exon 14-mutated NSCLC

    Phase 2 study results indicate that savolitinib has promising antitumor activity in Chinese patients with non-small-cell lung cancer harboring MET exon 14 skipping alterations, including those with pulmonary sarcomatoid carcinoma.

  2. 21-02-2020 | ASCO GU 2020 | News | Article

    Durvalumab–savolitinib duo has potential in metastatic papillary renal cell carcinoma

    Patients with metastatic papillary renal cell carcinoma are likely to benefit from the durvalumab–savolitinib combination, show findings from the 1-year follow-up of the CALYPSO trial. This independent news story was supported by an educational grant from Pfizer and Merck KGaA

  3. 01-04-2019 | Non-small-cell lung cancer | Video | Article

    Researcher comment: TATTON trial of savolitinib plus osimertinib in EGFR-mutated, MET-amplified NSCLC

    Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).

  4. 13-07-2017 | Renal cell carcinoma | News | Article

    Savolitinib has potential in MET-driven papillary RCC

    Savolitinib, a highly selective MET tyrosine kinase inhibitor, shows activity in patients with MET-driven advanced papillary renal cell carcinoma, researchers report.

  5. play
    25-02-2021 | ASCO GU 2021 | Conference coverage | Video

    Cabozantinib benefit for metastatic papillary RCC demonstrated

    Sumanta Pal provides an overview of the phase 2 SWOG 1500 study pitting the MET inhibitors cabozantinib, crizotinib, and savolitinib against sunitinib for the treatment of metastatic papillary renal cell carcinoma.

  6. 14-02-2021 | ASCO GU 2021 | Conference coverage | Article

    SWOG 1500: Cabozantinib ‘new standard’ for metastatic papillary RCC

    However, the prespecified futility analysis after 15 PFS events in each experimental arm and 20 events in the sunitinib arm led to closure of the crizotinib and savolitinib arms, Pal said.

  7. play
    29-05-2020 | ASCO 2020 | Conference coverage | Video

    Researcher comment: The SAVOIR trial

    Toni Choueiri discusses how the phase 3 SAVOIR trial of savolitinib in MET-driven papillary renal cell carcinoma could inform future research despite being terminated early (4:23).

  8. 20-01-2020 | Non-small-cell lung cancer | News | Article

    Crizotinib active against NSCLC with MET exon 14 alterations

    Although crizotinib was the first MET tyrosine kinase inhibitor to be evaluated in this patient group, promising data have since been reported for the more selective agents capmatinib, tepotinib, and savolitinib, say the researchers.

  9. 03-04-2019 | Non-small-cell lung cancer | News | Article

    Osimertinib combinations promising for NSCLC patients with acquired resistance to EGFR–TKIs

    Data from the phase Ib TATTON trial suggest that patients with EGFR -mutated non-small-cell lung cancer who have progressed on prior EGFR–tyrosine kinase inhibitor therapy could benefit from adding either the MET inhibitor savolitinib or the MEK inhibitor selumetinib to osimertinib.

  10. 01-04-2019 | Non-small-cell lung cancer | Video | Article

    Expert commentary: TATTON trial – Exploring options for EGFR inhibitor-resistant NSCLC

    Roy Herbst provides his views on the phase Ib TATTON study that combined osimertinib with either the MET inhibitor savolitinib or the MEK inhibitor selumetinib in the advanced, resistant NSCLC setting (2:53).

  11. 21-02-2019 | Renal cell carcinoma | News | Article
    ASCO GU 2019

    Immunotherapy-based regimens show promise in non-clear-cell RCC

    Durvalumab was administered at a monthly dose of 1500 mg, while savolitinib was given at a once-daily dose of 600 mg, with a 4-week run-in for savolitinib.

  12. 28-04-2017 | Genitourinary cancers | Conference report | Article

    Highlights from the 2017 Genitourinary Cancer Symposium (ASCO-GU), Orlando, Florida, USA

    Choueiri from Boston (MA, USA) presented interesting data on the application of a potent MET inhibitor, savolitinib, in patients with advanced papillary renal cell carcinoma (PRCC) [3].

  13. 04-08-2016 | Renal cell carcinoma | Article

    Medical treatment of renal cancer: new horizons

    Ongoing phase 2 trials are assessing the role of the MET inhibitors savolitinib, cabozantinib and crizotinib in pRCC (NCT02761057 and NCT02127710).

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.